UHS Universal Health Services
Durable hospital and behavioral franchise at under 8x EBIT; the market is pricing policy fear, not the economics.
The story
UHS runs acute care hospitals and the largest US behavioral health platform. Its moat comes from local density and certificate-of-need barriers, and demand for behavioral health keeps growing. It is a mature, cash-generative operator that has rebuilt margins to about 12% after the labor squeeze. The next leg of value depends on holding those margins while Medicaid supplemental payments and exchange subsidies come under policy pressure.
I kept the prior drivers because TTM revenue of $18.1B and a 12% margin confirm the story. I trimmed the target margin slightly to 11.5% because the current 12% includes state directed-payment windfalls that federal Medicaid reforms phase down. A roughly 150% implied upside on a heavily covered name also calls for conservatism rather than extrapolating peak margins.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 7y |
| Target operating margin | 11.5% |
| Years to target margin | 3 |
| Sales-to-capital | 1.48 |
| Beta | 1.00 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.3% |
| Terminal WACC | 8.3% |
Valuation bridge
| PV of explicit FCFF | 6.78B |
| PV of terminal value | 17.75B |
| Equity value | 19.59B |
| ÷ shares → per share | $332.33 |
News
bullish +0.30 · 8 articles
- Can Tenet Healthcare Sustain Growth Despite Lower Surgical Volumes?
- Universal Health Services Stock: Is UHS Underperforming the Health Care Sector?
- How Acadia Healthcare Is Turning Capacity Growth Into Cash Flow
- CVS Still Sees 'High-Trend' Cost Growth; Oscar, UNH Stock Fall
- Can Operational Resiliency Protect HCA's Long-Term Profitability?
- Why Is Universal Health Services (UHS) Up 5.7% Since Last Earnings Report?
- Universal Health Services (UHS) Stock Looks Undervalued As Returns Already Look Strong
- Universal Health Services Stock: Analyst Estimates & Ratings
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 19.20B | 6.0% | 11.9% | 1.74B | 734.37M | 1.01B | 932.67M |
| 2 | 20.24B | 5.4% | 11.7% | 1.81B | 702.75M | 1.11B | 945.31M |
| 3 | 21.22B | 4.8% | 11.5% | 1.87B | 661.04M | 1.21B | 951.98M |
| 4 | 22.12B | 4.2% | 11.5% | 1.95B | 609.35M | 1.34B | 974.49M |
| 5 | 22.93B | 3.7% | 11.5% | 2.02B | 548.06M | 1.47B | 989.07M |
| 6 | 23.64B | 3.1% | 11.5% | 2.08B | 477.77M | 1.61B | 995.60M |
| 7 | 24.23B | 2.5% | 11.5% | 2.14B | 399.32M | 1.74B | 994.14M |
Key risks
- Medicaid supplemental and directed-payment cuts and expiring ACA subsidies compress acute-care margins
- Labor cost reinflation in nursing and behavioral staffing
- Behavioral health regulatory and litigation exposure (large jury verdicts)
Catalysts
- Continued behavioral volume and pricing strength with buybacks shrinking the share count
- Clarity on state directed-payment approvals that removes the policy overhang
⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.